MA-CONFORMATION-X-THER
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Celebrates Innovators Driving Global Progress at 2025 Awards14.1.2025 21:15:00 CET | Press release
Today, His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, recognised the 2025 winners of the Zayed Sustainability Prize. Celebrating the transformational impact of 11 pioneering organisations and high schools from across the world, the Prize reflects the UAE’s commitment to fostering scalable solutions to global challenges and empowering communities in their pursuit of sustainable prosperity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114367660/en/ Zayed Sustainability Prize celebrates innovators driving global progress at 2025 Awards (Photo: AETOSWire) In a Ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by 11 Heads of State, Ministers, and business leaders, H.H. Sheikh Mohamed bin Zayed awarded the winners for their remarkable achievements, encouraging continued innovation in every corner of the globe. H.H. Sheikh Mohamed bin Zayed said: “The UAE remains steadfast in its co
Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market14.1.2025 18:07:00 CET | Press release
Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe. This press release features multimedia. View the full release here: https://www.businessw
Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution14.1.2025 17:45:00 CET | Press release
Verimatrix DVB Access completes Cartesian’s Farncombe Security® Audit Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air (OTA) Conditional Access System (CAS). The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security® Audit. DVB ReAccess addresses a notable hurdle for one-way networks such as broadcast satellite providers that lack bidirectional handshakes to identify and authenticate client devices authorized to decrypt content. In one-way networks, the security of content relies almost exclusively on the resistance and resilience of the CAS, the most secure of which have a client software deeply anchored within the device’s hardware, leveraging a number of security features provided by the chipset. Conseque
Kymeta Welcomes Industry Leaders to Board of Advisors14.1.2025 17:00:00 CET | Press release
The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/ (Graphic: Business Wire) The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private se
Dfns Secures $16M to Expand its Crypto Wallet Infrastructure for Finance14.1.2025 16:00:00 CET | Press release
Dfns, the leading wallet-as-a-service platform for crypto assets, has successfully closed a $16 million Series A, led by Further Ventures, the venture arm of Abu Dhabi’s largest sovereign wealth fund, ADQ. This round also saw participation from historic investors such as White Star Capital, Hashed, Semantic, Techstars, and Bpifrance, alongside new backers including Motive Partners, Wintermute, and Motier Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114288142/en/ (Photo: Business Wire) Our Institutional Focus Paid Off Two years ago, Dfns made a strategic up-market move focusing mainly on institutional clients. The company’s vision has remained steadfast: institutional investors hold the key to driving crypto adoption as they have the lion’s share of the global liquidity. To appeal to them, Dfns prioritized uncompromising bank-grade security, aligning with standard traditional financial systems and leveraging st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom